Nanotechnological based miRNA intervention in the therapeutic management of neuroblastoma

Faheem Hyder Pottoo; Md Abul Barkat; Harshita; Mohammad Azam Ansari; Md Noushad Javed; Qazi Mohammad Sajid Jamal; Mohammad Amjad Kamal

doi:10.1016/j.semcancer.2019.09.017

Nanotechnological based miRNA intervention in the therapeutic management of neuroblastoma

Semin Cancer Biol. 2021 Feb:69:100-108. doi: 10.1016/j.semcancer.2019.09.017. Epub 2019 Sep 25.

Authors

Faheem Hyder Pottoo¹, Md Abul Barkat², Harshita², Mohammad Azam Ansari³, Md Noushad Javed⁴, Qazi Mohammad Sajid Jamal⁵, Mohammad Amjad Kamal⁶

Affiliations

¹ Department of Pharmacology, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, P. O. Box 1982, Dammam 31441, Saudi Arabia.
² Department of Pharmaceutics, College of Pharmacy, University of Hafr Al Batin, Al Jamiah, Hafr Al Batin 39524, Saudi Arabia.
³ Department of Epidemic Disease Research, Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, P. O. Box 1982, Dammam 31441, Saudi Arabia. Electronic address: maansari@iau.edu.sa.
⁴ Department of Pharmaceutics, School of Pharmaceutical Education and Research (SPER), Jamia Hamdard, New-Delhi, India; School of Pharmaceutical Sciences, Apeejay Stya University, Gurugram, Haryana, India. Electronic address: rxnoushad@gmail.com.
⁵ Department of Health Informatics, College of Public Health and Health Informatics, Qassim University, Saudi Arabia.
⁶ King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589, Saudi Arabia; Enzymoics, 7 Peterlee Place, Hebersham, NSW, 2770, Australia; Novel Global Community Educational Foundation, Australia.

PMID: 31562954
DOI: 10.1016/j.semcancer.2019.09.017

Abstract

Neuroblastoma (NB) is a widely diagnosed cancer in children, characterized by amplification of the gene encoding the MYCN transcription factor, which is highly predictive of poor clinical outcome and metastatic disease. microRNAs (a class of small non-coding RNAs) are regulated by MYCN transcription factor in neuroblastoma cells. The current research is focussed on identifying differential role of miRNAs and their interactions with signalling proteins, which are intricately linked with cellular processes like apoptosis, proliferation or metastasis. However, the therapeutic success of miRNAs is limited by pharmaco-technical issues which are well counteracted by nanotechnological advancements. The nanoformulated miRNAs unload anti-cancer drugs in a controlled and prespecified manner at target sites, to influence the activity of target protein in amelioration of NB. Recent advances and developments in the field of miRNAs-based systems for clinical management of NBs and the role of nanotechnology to overcome challenges with drug delivery of miRNAs have been reviewed in this paper.

Keywords: Metastasis; Nanoformulations; Nanotherapeutics; Neuroblastoma; miRNAs.

Publication types

Review

MeSH terms

Animals
Antineoplastic Agents / administration & dosage*
Disease Management
Drug Delivery Systems*
Gene Expression Regulation, Neoplastic / drug effects*
Humans
MicroRNAs / administration & dosage*
MicroRNAs / genetics
Nanoparticles / administration & dosage*
Nanoparticles / chemistry
Nanotechnology / methods*
Neuroblastoma / drug therapy*
Neuroblastoma / genetics
Neuroblastoma / pathology

Substances

Antineoplastic Agents
MicroRNAs